Effect on ribonucleotide reductase of novel lipophilic iron chelators: the desferri-exochelins.
D001943:Breast Neoplasms / Q000201:enzymology / Q000378:metabolism; D045744:Cell Line, Tumor; D004247:DNA / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D004261:DNA Replication / Q000187:drug effects; D003676:Deferoxamine / Q000494:pharmacology; D004578:Electron Spin Resonance Spectroscopy; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D005609:Free Radicals / Q000378:metabolism; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007502:Iron Chelating Agents / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D010456:Peptides, Cyclic / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D014443:Tyrosine / Q000737:chemistry / Q000378:metabolism
D004791:Enzyme Inhibitors; D005609:Free Radicals; D007502:Iron Chelating Agents; D010456:Peptides, Cyclic; C410730:desferriexochelin 772SM; C010953:exochelins; D014443:Tyrosine; D004247:DNA; D012264:Ribonucleotide Reductases; D003676:Deferoxamine